Brief: Trevi Therapeutics To Present Final Data From Phase 2 Trial Of Oral Nalbuphine Extended Release For Chronic Cough In Ipf At Bts' Winter Meeting

Trevi Therapeutics

27/10/2022 13:01

Oct 27 (Reuters) - Trevi Therapeutics Inc  TRVI.O :
    * TREVI THERAPEUTICS TO PRESENT FINAL DATA FROM PHASE 2
TRIAL OF
ORAL NALBUPHINE EXTENDED RELEASE FOR CHRONIC COUGH IN IPF AT
BTS' WINTER MEETING
    * TREVI THERAPEUTICS INC- DATA FROM FULL SET OF SUBJECTS WAS
STATISTICALLY SIGNIFICANT FOR PRIMARY EFFICACY ENDPOINT
    * TREVI THERAPEUTICS INC- KEY SECONDARY PATIENT AND
CLINICIAN-REPORTED OUTCOMES SUPPORTED POSITIVE PRIMARY ENDPOINT

Source text for Eikon:  ID:nPnNpDCda 
Further company coverage:  TRVI.O 
 ((Reuters.Briefs@thomsonreuters.com;))